<DOC>
	<DOC>NCT00969813</DOC>
	<brief_summary>This study is designed to evaluate how CP-690,550 is handled by the body in healthy volunteers who have mild and moderate hepatic impairment compared to healthy volunteers with normal hepatic function. This study will also evaluate the safety and tolerability of CP-690,550.</brief_summary>
	<brief_title>A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Healthy volunteers who have normal liver function, and subjects who have either mild or moderate liver impairment. Subjects with severe liver impairment Subjects who have weakened immune systems</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Hepatic impairment</keyword>
</DOC>